Terminé

A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est collecté

Collecte de données

Qui peut participer

Infections transmises par le sang+15

+ Maladies génito-urinaires

+ Maladies Génitales

Voir tous les critères d'éligibilité
Comment se déroule l'étude

Observationnel
Date de début : octobre 1997
Voir le détail du protocole

Résumé

Sponsor principalNational Cancer Institute (NCI)
Dernière mise à jour : 4 mars 2008
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 octobre 1997

Date à laquelle le premier participant a commencé l'étude.

The factors that influence HIV disease progression are not well understood. While larger amounts of circulating virus (high 'viral loads') predict future adverse clinical events, many of the clinical factors responsible for high viral loads and disease progression remain unknown. Certain clinical events and defined interventions are associated with increases in plasma viral RNA concentrations. One of these clinical interventions is immunization; immunization with several vaccines have been shown to increase plasma HIV RNA concentrations. Even though vaccination can lead to transient increases in plasma HIV concentrations, certain vaccines, including influenza vaccine, are still recommended for HIV patients because the risks of the disease targeted by the immunization are held to be greater than the immunization itself. Therefore, immunization with influenza vaccine can be considered a model, clinically indicated intervention, given at a known time which stimulates HIV replication. For influenza immunization, and for other treatments leading to increases in viral RNA concentrations, detailed knowledge of the regulatory events that mediate the increase in RNA concentrations is not available. We hypothesize that immunization with influenza vaccine, and perhaps other immune stimulatory events, lead to an increase in HIV replication through a regulatory system involving cytokines, signal transduction systems, transcription factors, effects on the cell cycle, and increased expression of additional gene products needed for viral replication, such as genes of the nucleic acid biosynthetic pathways. While experiments aimed at investigating one or another particular part of this regulatory system can be performed with traditionally available technologies, such technologies cannot provide comprehensive information concerning a large number of the regulatory events that may be involved in mediating the increase in HIV RNA concentration. In this protocol, we aim to develop the methodologies needed to determine changes in expression of many of the genes which may be involved in mediating the regulation of HIV expression in HIV-infected patients using cDNA microarray technologies. Once the methodologies are developed, such work may provide new insights into the regulatory systems controlling HIV expression in HIV-infected patients may provide new insights into the pathogenesis of HIV disease.

NCT00001681
Sponsor principalNational Cancer Institute (NCI)
Dernière mise à jour : 4 mars 2008
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

40 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

Volontaires sains autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

Infections transmises par le sangMaladies génito-urinairesMaladies GénitalesMaladies TransmissiblesSyndromes de Déficience ImmunologiqueMaladies du Système ImmunitaireInfectionsInfections à OrthomyxoviridaeMaladies des voies respiratoiresInfections des voies respiratoiresInfections à RetroviridaeInfections à virus ARNMaladies Sexuellement TransmissiblesMaladies viralesMaladies Sexuellement Transmissibles ViralesInfections à LentivirusGrippe, HumaineInfections à VIH

Critères

PATIENT VOLUNTEERS: HIV positive. CD4 cells greater than 200, obtained within the prior 2 months. Age greater than 18 years. Willing and able to participate in study. No immunomodulatory therapy, including other vaccinations within the prior 4 weeks. Stable therapy on G-CSF and/or thalidomide permitted. No contraindications for influenza vaccination. No clinical conditions that would place the patient at undo risk from the mandated protocol blood draws. No recent (less than 4 weeks) changes in antiviral therapy or change in antiviral therapy anticipated during the 3 week duration of the study. No history of recent (less than 4 weeks) or intercurrent blood transfusion or cytotoxic chemotherapy. Hemoglobin greater than 9.0 g/dl. Total volume of blood otherwise drawn should not exceed 500 ml over 6 weeks. No upper respiratory infections or other acute illnesses within the prior 2 weeks. CONTROL NORMAL VOLUNTEERS: Age greater than 18 years. Willing and able to participate in study. Healthy. No ongoing condition or recent (less than 4 weeks) illness requiring a physician's care. No upper respiratory infections or other acute illnesses within the prior 2 weeks. Total volume of blood drawn should not exceed 500 ml over 6 weeks. Not taking any prescription medications.

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

National Cancer Institute (NCI)

Bethesda, United StatesOuvrir National Cancer Institute (NCI) dans Google Maps
Terminé1 Centres d'Étude